Investment
Features
FeesSafety
Academy
More
Pluang+

Compare ARK Space & Defense Innovation ETF (ARKX) vs Gilead Sciences, Inc. (GILD) Price & Performance

ARK Space & Defense Innovation ETFTrade
Gilead Sciences, Inc.Trade

Price performance (Past 24H)

Key statistics

ARK Space & Defense Innovation ETF vs Gilead Sciences, Inc. — how do they compare? ARK Space & Defense Innovation ETF trades at $34.6, while Gilead Sciences, Inc. trades at $135.77 (market cap $168.35B). The key difference: Gilead Sciences, Inc. pays a 2.42% dividend while ARK Space & Defense Innovation ETF pays none, and ARK Space & Defense Innovation ETF is trading nearer its 52-week high, Gilead Sciences, Inc. nearer its low. Which is the better fit depends on your goals.

ARKXGILD
Sector
Sector/ThematicHealth
52-Week High
$37.74$155.80
52-Week Low
$25.46$110.56
Market Cap
$168.35B
Enterprise Value
$191.42B
Dividend Yield
2.42%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

ARK Space & Defense Innovation ETF

No Aura AI signal available yet.

Gilead Sciences, Inc.

Gilead Sciences (GILD) trades at $133.06, down slightly by 0.11% today, with a bullish technical signal supported by moving averages. The company reported strong Q2 2026 revenue growth of 8% year-over-year, beating estimates, though a net loss of $6.75 per share resulted from acquisition-related costs. Analyst consensus is strongly bullish with a $151.22 price target, and recent news highlights robust HIV drug sales and pipeline progress.

The outlook for GILD is positive, driven by raised 2026 guidance and HIV franchise strength, but risks include patent cliffs by the mid-2030s and integration challenges from acquisitions. Investors should weigh the high valuation multiples against growth potential, with the stock offering upside if execution continues to exceed expectations.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About ARK Space & Defense Innovation ETF

ARKX is an actively managed ETF that invests in companies leading space exploration and defense innovation. It focuses on orbital and sub-orbital aerospace, reusable rockets, and enabling technologies like AI, robotics, and satellite systems.

Read more on ARKX

About Gilead Sciences, Inc.

Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.

Read more on GILD